Focus: Context Therapeutics is a Philadelphia-based biotech company focused on developing novel treatments for hormone-driven cancers, including breast cancer, ovarian cancer, and endometrial adenocarcinoma. The company operates at an early-stage with a pipeline of 9 active programs primarily in Phase 1 and Phase 2 development.
Profile data last refreshed 3h ago · AI intelligence enriched 3w ago
Best suited for early-career scientists and clinicians seeking R&D ownership in a focused oncology biotech, but limited hiring and pre-revenue status present execution risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Context Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Context Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo